Davenport & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $861K | Buy |
20,464
+373
| +2% | +$11.9K | ﹤0.01% | 825 |
|
|
2026
Q1 | $531K | Buy |
20,091
+322
| +2% | +$9.43K | ﹤0.01% | 912 |
|
|
2025
Q4 | $573K | Sell |
19,769
-86
| -0.4% | -$2.58K | ﹤0.01% | 859 |
|
|
2025
Q3 | $551K | Sell |
19,855
-287
| -1% | -$7.25K | ﹤0.01% | 868 |
|
|
2025
Q2 | $490K | Sell |
20,142
-75
| -0.4% | -$1.64K | ﹤0.01% | 881 |
|
|
2025
Q1 | $420K | Buy |
20,217
+838
| +4% | +$21.1K | ﹤0.01% | 891 |
|
|
2024
Q4 | $456K | Buy |
19,379
+150
| +0.8% | +$3.69K | ﹤0.01% | 873 |
|
|
2024
Q3 | $492K | Sell |
19,229
-1,591
| -8% | -$40.5K | ﹤0.01% | 830 |
|
|
2024
Q2 | $489K | Buy |
20,820
+173
| +0.8% | +$4.37K | ﹤0.01% | 806 |
|
|
2024
Q1 | $594K | Buy |
20,647
+1,018
| +5% | +$30.6K | ﹤0.01% | 756 |
|
|
2023
Q4 | $644K | Buy |
19,629
+200
| +1% | +$5.44K | ﹤0.01% | 696 |
|
|
2023
Q3 | $541K | Buy |
19,429
+38
| +0.2% | +$1.24K | ﹤0.01% | 703 |
|
|
2023
Q2 | $661K | Sell |
19,391
-60
| -0.3% | -$1.89K | ﹤0.01% | 672 |
|
|
2023
Q1 | $585K | Sell |
19,451
-18
| -0.1% | -$558 | ﹤0.01% | 676 |
|
|
2022
Q4 | $550K | Sell |
19,469
-1,076
| -5% | -$34.1K | ﹤0.01% | 657 |
|
|
2022
Q3 | $675K | Sell |
20,545
-92
| -0.4% | -$3.38K | 0.01% | 594 |
|
|
2022
Q2 | $650K | Sell |
20,637
-117
| -0.6% | -$4.09K | 0.01% | 607 |
|
|
2022
Q1 | $953K | Sell |
20,754
-1,332
| -6% | -$63.5K | 0.01% | 561 |
|
|
2021
Q4 | $1.35M | Sell |
22,086
-91
| -0.4% | -$6.29K | 0.01% | 497 |
|
|
2021
Q3 | $1.66M | Buy |
22,177
+614
| +3% | +$51.5K | 0.01% | 426 |
|
|
2021
Q2 | $2M | Sell |
21,563
-723
| -3% | -$61.5K | 0.02% | 333 |
|
|
2021
Q1 | $1.98M | Sell |
22,286
-2,421
| -10% | -$240K | 0.02% | 283 |
|
|
2020
Q4 | $2.3M | Buy |
24,707
+87
| +0.4% | +$6.93K | 0.02% | 256 |
|
|
2020
Q3 | $1.57M | Sell |
24,620
-678
| -3% | -$39.7K | 0.02% | 272 |
|
|
2020
Q2 | $1.32M | Buy |
25,298
+1,558
| +7% | +$66.8K | 0.02% | 288 |
|
|
2020
Q1 | $743K | Buy |
23,740
+6,200
| +35% | +$207K | 0.01% | 340 |
|
|
2019
Q4 | $588K | Buy |
17,540
+4,030
| +30% | +$128K | 0.01% | 439 |
|
|
2019
Q3 | $466K | Sell |
13,510
-600
| -4% | -$19.5K | 0.01% | 460 |
|
|
2019
Q2 | $486K | Buy |
14,110
+3,185
| +29% | +$102K | 0.01% | 450 |
|
|
2019
Q1 | $359K | Buy |
10,925
+1,250
| +13% | +$36.9K | ﹤0.01% | 500 |
|
|
2018
Q4 | $232K | Buy |
9,675
+1,200
| +14% | +$33.8K | ﹤0.01% | 563 |
|
|
2018
Q3 | $283K | Buy |
8,475
+1,075
| +15% | +$34K | ﹤0.01% | 568 |
|
|
2018
Q2 | $215K | Buy |
+7,400
| New | +$206K | ﹤0.01% | 632 |
|
Other funds holding ARKG
JFG
Davenport & Co's ARKG Position: Q2 2026 in Review
Davenport & Co increased its ARK Genomic Revolution ETF (ARKG) stake by 1.9% in Q2 2026, buying an estimated $11.9K and bringing the position to 20,464 shares worth $861K. The position accounts for ﹤0.01% of the portfolio, ranked #825.
Davenport & Co first reported a position in ARKG in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.3M in Q4 2020. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.
- Davenport & Co held 20,464 shares of ARK Genomic Revolution ETF worth $861K as of Q2 2026.
- Davenport & Co bought 373 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $11.9K.
- ARK Genomic Revolution ETF made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #825 holding.
- Davenport & Co first reported a position in ARK Genomic Revolution ETF in Q2 2018 and has held it in 33 quarters since.
- Davenport & Co's ARK Genomic Revolution ETF position peaked at $2.3M in Q4 2020.
- 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.
Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.